Back to search results

Cardiac MRI for Right Atrial Clot in Cancer Patients

This study is looking at how well a special type of imaging, called Cardiac Magnetic Resonance Imaging (CMR), can help doctors understand central venous catheter-associated right atrial clots (RA clots) in people with cancer. RA clots are blood clots that form in the right upper chamber of the heart, often linked to catheters used for treatment. The goal is to see if CMR can provide detailed information about these clots, which could help doctors choose the best treatment. You might be able to join if you are an adult with any type of cancer and are suspected to have an RA clot based on other tests like an echocardiogram or chest CT scan. The study aims to enroll 150 participants and is currently unclear about its recruitment status.

Study design
This is an interventional study planning to enroll 150 adult participants. It will use Cardiac MRI as a diagnostic test.
What's involved
You would have a Cardiac MRI scan at the beginning of the study, within one month of your suspected RA clot diagnosis, and another follow-up scan at 3 months.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 3 months to assess the association between the clot and the Cardiac MRI tissue.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07549477

A Study of Cardiac Magnetic Resonance Imaging (CMR) for Evaluating Catheter-Associated Right Atrial Clot in People With Cancer

Recruiting
NAAges 18+InterventionalDiagnostic
Memorial Sloan Kettering Cancer Center
~150 participants
Updated 2026-04-24 on ClinicalTrials.gov
What's tested:Cardiac MRI

At a glance

Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
association between Central venous catheter-associated right atrial thrombus (RATHR) with Cardiac MRI (CMR) tissue
Measured over up to 3 months

Conditions

Adult Cancer Patients
Right Atrial Clot

Explore related trials

Hematologic NeoplasmRight Atrial ClotSolid Neoplasm

NCT07549477

Where you'd take part

This study runs at 7 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Memorial Sloan Kettering Basking Ridge (Consent Only)

    Basking Ridge, New Jerseystudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Bergen (Consent Only )

    Montvale, New Jerseystudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Cancer Center (All Protocol Activites)

    New York, New Yorkstudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Monmouth (Consent Only)

    Middletown, New Jerseystudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Nassau (Consent Only)

    Uniondale, New Yorkstudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Suffolk- Commack (Consent Only)

    Commack, New Yorkstudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Westchester (Consent Only)

    Harrison, New Yorkstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Angel Chan, MD, PhD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Angel Chan, MD, PhD
[email protected]
212-639-7217
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Documentation of Disease
Definition of Disease \[or Measurable Disease\]
Cardiac mass (CMASS) will be initially localized on cine-CMR, on which it is defined via established criteria as a discrete tissue prominence independent from normal anatomic structures, quantified based on size (area, cross-sectional linear dimensions)
CMASS will be further categorized by type (CNEO or CTHR) based on CMR tissue characterization: CNEO and CTHR can be differentiated based on presence of contrast enhancement via the reference standard of LGE-CMR using established criteria previously validated by our group and others.
CTHR is defined as discrete mass(es) with avascular tissue properties (enhancement absent).
CTHR will be further subgrouped into RATHR after confirmation of its location and in relation to CVC.
CNEO is defined as discrete mass(es) with vascular tissue properties (enhancement present),
CNEO can be further sub-typed based on visually scored magnitude of enhancement (diffusely hyper-enhancing, mixed, predominantly hypo-enhancing) in accordance with established methods previously used by our group.
Required Organ Function:
Creatinine clearance (CrCL) of ≥30 mL/min by the Cockcroft-Gault formula (Note: For agents for which renal excretion is not a major route of clearance and for which renal toxicity is not an issue, the threshold for creatinine clearance should be ≥30 mL/min.):
Allergies
No history of allergic reaction to the gadolinium contrast agent or compounds of similar chemical or biologic composition
Subjects in RATHR+ group must meet the following criteria:
Adult cancer patients (stage I-IV) who are greater than 18 years of age
Presence of indwelling central venous catheter (Mediport, PICC, Hickman, pheresis cath, etc) with a minimal duration of 7 days prior to CMR
Presence of RATHR based on established CMR criteria (i.e. absence of enhancement on LGE-CMR)
Patients who underwent CMR within the past 3 months for evaluation of cardiac masses are eligible if confirmed for the presence of RATHR

Exclusion

Known pre-existing CV disease which can affect hemodynamics within cardiac chambers as determined by the investigator, including
Arrhythmia - chronic persistent atrial arrhythmias
Cardiomyopathies including Ischemic or non-ischemic cardiomyopathy with LVEF \<53%
Restrictive cardiomyopathy - cardiac amyloidosis, myocardial fibrosis
Constrictive pericarditis
Valvular heart disease with equal to or greater than moderate stenosis or regurgitation
Cardiac neoplastic involvement
Subjects will be excluded if they are unable to provide informed consent due to underlying clinical conditions and mental status.
Subjects will be excluded for getting CMR if they are
Subjects who would be normally excluded from undergoing a MRI examination as per institutional standard of care. At MSK, patients will be screened by radiology technicians using Memorial Hospital for Cancer and Allied Diseases Screening Questionnaire (Appendix 1) prior to getting cardiac MRI
Subjects with presence of MRI incompatible metal fragments, aneurysm clip, implants or devices that would warrant avoidance of a strong magnetic field
Contraindications to receive gadolinium contrast
Renal dysfunction (GFR \<30 mL/min) or end stage renal disease
Prior allergic reaction to gadolinium
Subject who are unable to tolerate CMR due to clinical status, respiratory compromise, or severe claustrophobia
Female participants who are pregnant or nursing
Subjects defined as vulnerable populations, as defined by 45 CFR 46
Participants at higher risk due to age, frailty, or the emergent nature of their condition

What this trial measures

  • association between Central venous catheter-associated right atrial thrombus (RATHR) with Cardiac MRI (CMR) tissueup to 3 months

    Quantitative tissue characterization of RATHR will be employed to measure RATHR organization based on contrast infiltration, T1 variability altered T2\*10 and susceptibility. These will be used to determine chronicity of thrombi as a predictor of therapeutic response to anticoagulation. Analyses will also include assessment of RATHR size, and geometry (border irregularity) at baseline and at 3-month follow up CMR using established methods to assess for the degree of resolution of RATHR.